The company’s lead in-house project is BT1718 – a bicycle toxin conjugate (BTC) drug that combines targeting of MT1-MMP on cancer cells with a cell-killing payload – which is being tested in ...

Inactive metalloproteinases can be activated through proteolytic cleavage by either membrane-type matrix metallproteinase 1 (MT1-MMP) or plasmin, and inhibited by binding to specific inhibitors ...